Keyphrases
Tumor Immunity
100%
Cyclin-dependent Kinase 6 (CDK6)
100%
Cyclin-dependent Kinase 4/6 Inhibitors
100%
Tumor Cells
71%
Regulatory T Cells
28%
Solid Tumors
28%
Double-stranded RNA
14%
Phosphorylation
14%
Mouse Model
14%
Clinical Trials
14%
Cell Cycle Arrest
14%
Breast Cancer
14%
Retinoblastoma Tumor Suppressor
14%
E2F Target Genes
14%
Malignancy
14%
Cytotoxic T Cells
14%
Pharmacological Inhibitors
14%
Breast Carcinoma
14%
Cellular Expression
14%
Mechanism of Action
14%
T-cell Mediated
14%
Reducing Activity
14%
Transcriptome Analysis
14%
Antitumor Immune Response
14%
Intracellular Level
14%
Target DNA
14%
Combination Regimen
14%
Serial Biopsy
14%
DNA Methyltransferase 1 (DNMT1)
14%
Inhibitor Treatment
14%
Tumor Immunogenicity
14%
Type III Interferon
14%
New Combination
14%
Immune Checkpoint Blockade
14%
G1 Cell Cycle Arrest
14%
Anticancer Treatment
14%
Tumor Antigen Presentation
14%
Endogenous Retroviral Element
14%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Cyclin Dependent Kinase 4
100%
Cyclin Dependent Kinase 6
100%
Solid Malignant Neoplasm
20%
Clinical Trial
10%
Malignant Neoplasm
10%
Mouse Model
10%
Breast Cancer
10%
Immunotherapy
10%
Immunogenicity
10%
Tumor Antigen
10%
Breast Carcinoma
10%
Tumor Suppressor Protein
10%
Interferon Type III
10%
Retinoblastoma
10%
Double Stranded RNA
10%
DNA (Cytosine 5) Methyltransferase 1
10%